Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
Brain
Seyltx Announces Results of Electronic Health Record Analysis to Determine the Prevalence of Refractory Chronic Cough
- Data will be presented at the London International Cough Symposium on July 18, 2024 - 54,958,289 adult patients in...
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of...
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August...
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
Sarma1 2 Dr. Purnanand Sarma, PhD Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and...
New4med GmbH Announces First Cases of its novel Basivertebral Nerve Ablation (BVNA)
LADENBURG, Germany, July 8, 2024 /PRNewswire/ -- New4med GmbH, a German startup focused on innovative spinal treatments, announces the successful European...
Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
The first clinical case was performed at Brigham and Women’s Hospital The clinical trial is expected to support the future...
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia Approximately 10 million adults in...
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Transforming Children’s Lives: DP World’s Aviv Clinics Dubai’s Revolutionary Youth Protocol
DUBAI, United Arab Emirates, July 07, 2024 (GLOBE NEWSWIRE) -- At DP World's Aviv Clinics Dubai, the world’s most advanced...
DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer’s Disease
BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416,...
IRLAB: Invitation to the Interim Report for Q2 2024 Presentation and Webcast
GOTHENBURG, SE / ACCESSWIRE / July 08, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 8, 2024 - IRLAB Therapeutics...
Corundum Neuroscience Awards Research Grant to Explore Machine Learning for Non-Invasive Detection of Dementia-Associated Brain Activity During Sleep
Research Project with Tel Aviv University to Focus on Optimizing Identification of Early-Stage Dementia and Improving Diagnosis and Treatment for...
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival...
Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's diseaseMarks latest step in Mission's...
IRLAB’s Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee
GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 2, 2024 - IRLAB Therapeutics...
Neuroglee Health Selected for CMS GUIDE Model Program and Announces Company Name Evolution
BOSTON, July 1, 2024 /PRNewswire/ -- Neuroglee Health, a leading cognitive care solutions company, announced today that it was selected to...
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious...
Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes
SEATTLE and VANCOUVER, British Columbia, July 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson,...